Alzheimer; News from the web:
Today, we are living history: the U.S. Food and Drug Administration (FDA) granted traditional approval of lecanemab, sold under the brand name Leqembi, for the treatment of early-stage Alzheimer’s disease. This is the first traditional approval granted for an Alzheimer’s treatment that changes the underlying course of the disease. Learn more here.
In addition, the Centers for Medicare & Medicaid Services (CMS) announced it will cover the treatment through Medicare. Read our statement here.
Read all about it HERE